| Web: | mayocliniclabs.com |
|---|---|
| Email: | mcl@mayo.edu |
| Telephone: | 800-533-1710 |
| International: | +1 855-379-3115 |
| Values are valid only on day of printing | |
| Web: | mayocliniclabs.com |
|---|---|
| Email: | mcl@mayo.edu |
| Telephone: | 800-533-1710 |
| International: | +1 855-379-3115 |
| Values are valid only on day of printing | |
Our amyloid protein identification methodology is considered the gold standard because of the high sensitivity and accuracy with which it types amyloid proteins in paraffin-embedded specimens. By combining focused laser microdissection (LMD) of Congo red-positive amyloid plaques with the analytical power of liquid chromatography-tandem mass spectrometry (LC-MS/MS)-based proteomic analysis, LC-MS/MS identifies the amyloid type with 100% specificity and 98% sensitivity.
Amyloidosis Test menu
Amyloidosis is the buildup of abnormal misfolded proteins in the organs. The disease can be systemic and life-threatening, frequently affecting the kidneys, heart, or other vital organs. At least 36 different proteins cause amyloidosis, and the underlying pathogenesis of each type is unique.
Key testing
Advantages
Highlights
Matt Millen, ex-pro NFL player, who played on four Super Bowl-winning teams underwent a nearly six-year medical journey in search for answers. Finally, he was diagnosed with amyloidosis using a new testing methodology at Mayo Clinic.